Planet Labs Stock Is Down 67% From Its High. Time To Buy?

Planet Labs shares have fallen about 67% from their May peak, pressured by a $1.5 billion equity-dilution program, cautious Q3 revenue guidance, and concern over decelerating growth. First-half fiscal 2027 revenue rose 44% year over year to $210 million, while the reported $148 million loss included a $106 million non-cash warrant-liability fair-value adjustment and free cash flow exceeded $21 million. Analysts project revenue growth of 42% this fiscal year and 31% in fiscal 2028; following the sell-off, the stock's price-to-sales multiple has compressed from 49x to roughly 15x, though the article recommends only cautious, dollar-cost-averaged buying.

Analysis

PL's investability now hinges less on differentiated imagery collection and more on whether its government-led bookings convert into durable, multi-year contracted revenue without requiring repeated equity issuance. The announced capital program creates a persistent technical overhang: even if operating execution remains strong, a larger share count can absorb much of the benefit from revenue growth and keep the valuation multiple capped until management clarifies deployment, timing, and expected return on the capital. At 15x sales, the market is still underwriting unusually high growth and eventual software-like margins, leaving little tolerance for a bookings slowdown or lower renewal rates.

Near term, selling pressure can persist through the next earnings release and any issuance under the equity facility; a positive FCF period is insufficient evidence of self-funding when working-capital timing and non-cash expense adjustments may be material. The 1-3 month catalyst is evidence that federal demand is broadening beyond a concentrated set of agencies, alongside backlog/RPO growth that exceeds revenue growth and stable gross margin. Over 6-18 months, PL could gain strategic value as governments and commercial customers increasingly require persistent monitoring, but competition from higher-resolution tasking providers, defense primes, and alternative data vendors may limit pricing power even if demand expands.

Consensus may be too focused on the drawdown and headline net loss while underweighting the option value of a scaled historical imagery archive plus AI-enabled change detection. The offset is that uniqueness does not automatically create economic moat: customers can mix daily low-resolution monitoring with selective high-resolution imagery, reducing PL's ability to monetize its cadence advantage. A recovery thesis is falsified by decelerating remaining performance obligations/bookings, material gross-margin erosion, or guidance reductions; conversely, a disclosed large multi-year government award and constrained dilution would be the cleanest rerating trigger.

Key Decisions for Investors

• Maintain PL as watchlist/avoid initiating a full cash long before the next results; the missing diligence item is the cadence and intended use of the $1.5B equity facility. Reassess after earnings if backlog/RPO growth remains above revenue growth and management quantifies dilution limits.
• For a high-risk tactical position, initiate only a small PL starter after a post-earnings stabilization signal, then add over 1-3 months only if guidance is maintained or raised. Target a 2:1 reward/risk framework; exit on a revenue-guide cut, incremental financing beyond the disclosed program, or evidence of contract concentration.
• Express the relative thesis through long PL / short RKLB or a broad space proxy only after confirming PL's government-bookings acceleration. This isolates persistent-imagery software/data monetization from launch and space-hardware beta, but should not be put on without comparable valuation and borrow checks.
• Avoid treating NVDA or NFLX as read-through trades; their inclusion is promotional rather than an operational linkage. The more relevant watch items are procurement budgets, agency contract awards, and competitive imagery pricing.